HB 1501-FN (2022): relative to insurance coverage for pediatric autoimmune neuropsychiatric disorders.

Cite this page

Granite Record indexes the General Court’s record; it is not that record. Where a citation allows only one source, cite the General Court — every page here links to what it is drawn from. The date below is the day the page was read.

MLA
“HB 1501-FN (2022): relative to insurance coverage for pediatric autoimmune neuropsychiatric disorders.” Granite Record, https://graniterecord.org/bill/2022/hb1501. Accessed 24 Oct. 2026.
APA
Granite Record. (n.d.). HB 1501-FN (2022): relative to insurance coverage for pediatric autoimmune neuropsychiatric disorders. Retrieved 24 Oct. 2026, from https://graniterecord.org/bill/2022/hb1501
Chicago
Granite Record. “HB 1501-FN (2022): relative to insurance coverage for pediatric autoimmune neuropsychiatric disorders.” Accessed 24 Oct. 2026. https://graniterecord.org/bill/2022/hb1501.
BibTeX
@misc{bill-2022-hb1501, title = {HB 1501-FN (2022): relative to insurance coverage for pediatric autoimmune neuropsychiatric disorders.}, howpublished = {Granite Record}, url = {https://graniterecord.org/bill/2022/hb1501}, note = {Accessed 24 Oct. 2026} }

HB 1501-FN (2022)

relative to insurance coverage for pediatric autoimmune neuropsychiatric disorders.

  • Status: Referred for interim study
  • Term: 2021-2022
  • House committee: Commerce and Consumer Affairs
  • Subject: Insurance

The Story

It was introduced on January 5, 2022 and referred to the House Commerce and Consumer Affairs committee. The committee held work sessions on February 10, 2022 and March 3, 2022. The committee met in executive session on March 3, 2022 to vote on its recommendation. The committee voted unanimously, 18–0, to recommend that the House study it after the session ends, and the report was placed on the consent calendar. On March 15, 2022 the House voted to study it after the session ends on a voice vote. The committee held a work session on October 13, 2022. The committee met in executive session on October 19, 2022 to vote on its recommendation. The committee reported back on its interim study of the bill: “Not Recommended for Future Legislation”, by a vote of 17 to 0.

Sponsors

Hearings and Sessions

  • February 2, 2022, 2:00 PM: public hearing, House Commerce and Consumer Affairs, LOB302-304
  • February 10, 2022, 1:15 PM: subcommittee work session, House Commerce and Consumer Affairs, LOB 302-304
  • March 3, 2022, 10:00 AM: subcommittee work session, House Commerce and Consumer Affairs, LOB 302-304
  • March 3, 2022, 1:15 PM: executive session, House Commerce and Consumer Affairs, LOB302-304
  • October 13, 2022, 11:00 AM: full committee work session, House Commerce and Consumer Affairs, LOB 302-304
  • October 19, 2022, 10:00 AM: executive session, House Commerce and Consumer Affairs, LOB 302-304

Votes

  • March 15, 2022, House: Refer for Interim Study — voice vote, passed

The Docket

  • January 5, 2022: Introduced 01/05/2022 and referred to Commerce and Consumer Affairs
  • February 2, 2022: Public Hearing: 02/02/2022 2:00 p.m. LOB302-304
  • February 10, 2022: Subcommittee Work Session: 02/10/2022 01:15 pm LOB 302-304
  • March 3, 2022: Subcommittee Work Session: 03/03/2022 10:00 am LOB 302-304
  • March 3, 2022: Executive Session: 03/03/2022 1:15 p.m. LOB302-304
  • March 8, 2022: Committee Report: Refer for Interim Study (Vote 18-0; CC)
  • March 15, 2022: Refer for Interim Study: MA VV 03/15/2022
  • October 13, 2022: Full Committee Work Session: 10/13/2022 11:00 am LOB 302-304
  • October 19, 2022: Executive Session: 10/19/2022 10:00 am LOB 302-304
  • October 27, 2022: Interim Study Report: Not Recommended for Future Legislation (Vote 17-0)

From the General Court